SURI BioTech develops proprietary probiotic bacterial strains with validated mechanisms of action for targeted health applications. The company supplies bulk cultures and finished products that meet EU Qualified Presumption of Safety standards and are stable for 24 months at room temperature. Its portfolio includes infant gut‑colonization formulas and performance‑enhancing supplements for athletes, supported by in‑vitro efficacy testing and scalable manufacturing processes.
Funding
Funding not disclosed
Founders
Product
Problem
Infants often struggle with proper intestinal metabolism and gut colonization, while athletes face challenges in lactic acid metabolism after exercise, hindering performance and recovery. Current probiotic solutions may lack targeted mechanisms of action and proven efficacy for these specific needs.
Solution
Suri Biotech develops targeted probiotic strains with well-defined mechanisms of action to enhance gut health and metabolic function. Their products address intestinal colonization in infants and lactic acid metabolism in athletes, promoting overall well-being and performance recovery. Utilizing a unique R&D platform, Suri Biotech screens, identifies, and tests strains based on their metabolic capacity, ensuring targeted performance and validated efficacy through in vitro models mimicking the intestinal microbiome. These strains are available in bulk or as finished products, supported by regulatory guidance and marketing materials for distributors.
Target Audience
The primary target audience includes infants and mothers seeking to establish proper intestinal metabolism and gut colonization, as well as athletes aiming to improve performance and recovery through enhanced lactic acid metabolism.
Features
- Proprietary bacterial strains with proven mechanisms of action
- Solutions for infant gut colonization and intestinal metabolism
- Products designed to metabolize lactic acid and improve athletic performance and recovery
- Strains belonging to groups with Qualified Presumption of Safety (QPS) for human consumption in the European Union
- Guaranteed 24-month stability at room temperature
- Strains sold in bulk or as finished products
- Regulatory support and marketing guidelines for distributors